Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study

BACKGROUND: Resectable pancreatic cancer (RPC) is potentially resectable on admission, and the impact of neoadjuvant therapy on these tumors is controversial. Moreover, the safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiation therapy (NA...

Descripción completa

Detalles Bibliográficos
Autores principales: Masui, Toshihiko, Nagai, Kazuyuki, Anazawa, Takayuki, Kasai, Yosuke, Yogo, Akitada, Yoshimura, Michio, Mizowaki, Takashi, Uza, Norimitsu, Fukuda, Akihisa, Matsumoto, Shigemi, Kanai, Masashi, Isoda, Hiroyoshi, Kawaguchi, Yoshiya, Uemoto, Shinji, Hatano, Etsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557863/
https://www.ncbi.nlm.nih.gov/pubmed/37649318
http://dx.doi.org/10.1002/cam4.6470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557863/
https://www.ncbi.nlm.nih.gov/pubmed/37649318
http://dx.doi.org/10.1002/cam4.6470

Ejemplares similares